StockData

Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.51−0.30 (-10.68%)

Close on Nov 20, 2026Market cap $168.57MP/E –Yield –

Liminatus Pharma gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

No gross profit figures for Liminatus Pharma

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Liminatus Pharma figures

See a number that looks wrong?